Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Theracryf Plc

Market Cap 7.05M 6.12M 5.64M 5.29M 9.88M 675M 10.08M 67.3M 26.06M 326M 26.48M 25.91M 1.13B P/E Ratio 2026 *
-1.65x
P/E Ratio 2027 * -2.01x
Enterprise Value 4.9M 4.25M 3.92M 3.67M 6.87M 469M 7.01M 46.78M 18.11M 226M 18.4M 18.01M 787M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
54.35%
Yield 2026 *
-
Yield 2027 * -
1 day-2.04%
1 week+6.67%
1 month+9.09%
3 months+17.07%
6 months+14.29%
Current year+20.00%
1 week 0.22
Extreme 0.22
0.26
1 month 0.21
Extreme 0.21
0.27
Current year 0.18
Extreme 0.182
0.27
1 year 0.18
Extreme 0.175
0.3
3 years 0.18
Extreme 0.175
3.58
5 years 0.18
Extreme 0.175
9
10 years 0.18
Extreme 0.175
35
Manager TitleAgeSince
Chief Executive Officer 64 2020-09-30
Director of Finance/CFO - 2023-09-04
Chief Tech/Sci/R&D Officer - 2021-04-30
Director TitleAgeSince
Director/Board Member - 2015-10-13
Director/Board Member 64 2020-09-30
Director/Board Member - 2023-12-31
Date Insider Type Main position Quantity % Market Cap.
25-10-15
Tracarta Ltd.
BuyCompany 7,342,296 0.3448%
25-05-21Others

Director

422,727,272 19.8499%
25-03-03Buy

Chief Operating Officer

1,500,000 0.2945%
Change 5-day change 1-year change 3-year change Capi.($)
-2.04%+6.67%-5.88%-93.33% 7.05M
+1.65%+6.42%+53.16%+109.62% 54.82B
+0.03%-1.80%+49.57%+43.94% 43.27B
+2.93%-1.13%-16.01%-19.32% 21.79B
+6.13%-7.23%-0.66%+399.13% 19.92B
+0.81%-8.38%+12.77%-33.24% 15.67B
+0.53%+2.08%+8.89%-40.13% 15.26B
+1.77%+2.10%+29.35%+180.72% 13.22B
-5.27%+3.89%+90.88%+208.02% 11.58B
-1.74%-1.05%+12.88% - 11.94B
Average +0.48%-0.31%+23.49%+83.93% 20.75B
Weighted average by Cap. +1.15%+1.16%+31.94%+97.69%

Financials

2026 *2027 *
Net sales - -
Net income -3.35M -2.91M -2.68M -2.51M -4.69M -321M -4.79M -31.98M -12.38M -155M -12.58M -12.31M -538M -3.43M -2.98M -2.74M -2.57M -4.8M -328M -4.9M -32.73M -12.67M -158M -12.87M -12.6M -550M
Net Debt -2.15M -1.87M -1.72M -1.61M -3.01M -206M -3.08M -20.52M -7.95M -99.28M -8.07M -7.9M -345M 453K 394K 363K 340K 635K 43.42M 648K 4.33M 1.68M 20.93M 1.7M 1.67M 72.77M
Logo Theracryf Plc
TheraCryf plc is a clinical-stage drug development company focusing on brain disorders. The Company has a clinical and preclinical pipeline of indications, including addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. Its lead program, orexin-1 antagonist, is being developed towards the clinic to target addictive behaviors like binge eating disorder (BED). It is also advancing a clinical-stage asset, SFX-01, in the fatal brain cancer glioblastoma (GBM). SFX-01 is a patented form of sulforaphane which has shown potential in the treatment of various cancers, neurodevelopmental disorders and other diseases. It has licensed the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. The Company also has a candidate molecule dopamine active transport (DAT) inhibitor at a late preclinical stage targeting fatigue and narcolepsy.
Employees
9
Date Price Change Volume
26-06-11 0.2400 p -2.04% 2,147,740
26-06-10 0.2450 p +8.89% 15,202,040
26-06-09 0.2250 p 0.00% 2,655,393
26-06-08 0.2250 p 0.00% 1,866,675
26-06-05 0.2250 p 0.00% 902,405
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.003282USD
Average target price
0.0431USD
Spread / Average Target
+1,214.38%

Annual profits - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!